Table 1. Clinical characteristics and risk factors distribution of patients during TKI treatment or at the time of cardiovascular event.
| whole cohort | imatinib cohort | nilotinib cohort | p | |
|---|---|---|---|---|
| N° Patients | 110 | 58 | 52 | 0.094 |
| M/F | 66/44 | 31/27 | 35/17 | 0.061 |
| Median age (years, range) | 61 (29-83) | 59 (33-82) | 62 (29-83) | 0.088 |
| Median duration of CML (months, range) | 60 (3-252) | 84 (12-180) | 56 (3-228) | 0.019 |
| Median TKI exposure (months, range) | n.a. | 84 (12-180) | 24 (3-84) | 0.0014 |
| First-line (%) | n.a. | 58 (100) | 29 (55) | 0.0029 |
| Second-third line TKI (%) | n.a. | 0 (0) | 23 (45) | n.a. |
| History of smoking (%) | 34 (31) | 17 (29) | 17 (33) | 0.126 |
| Arterial Hypertension (%) | 36 (33) | 17 (29) | 19 (37) | 0.054 |
| Diabetes Mellitus (%) | 19 (17) | 9 (16) | 10* (19) | 0.088 |
| BMI (range) | 26±1,4 | 26,1±1,4 | 25,9±1,3 | 0.091 |
| Dyslipidaemia (%) | 35 (32) | 15 (26) | 20 (38) | 0.047 |
| Familiarity (%) | 58 (53) | 30 (52) | 28 (54) | 0.099 |
| Number of risk factor > 2 | 62 (56) | 29 (50) | 33 (63) | 0.048 |
| Number of risk factor ≥ 3 | 44 (40) | 18 (31) | 26 (50) | 0.041 |
| Total n° of cardiovascular events (%) | 17/110 (15) | 3/58 (5) | 14/52 (27) | 0.00011 |
| First line treatment (%) | n.a. | 3/58 (5) | 6/29 (21) | n.a. |
| Second-third line (%) | n.a. | 0/0 (0) | 8/23 (35) | n.a. |
| TKI treatment time to event (months) | 125, 132, 102 | 30 (range 18-72) | n.a. |
Abbreviation: CML chronic myeloid leukemia, TKI tyrosine kinase inhibitor, BMI body mass index, n.a. not applicable *2/10 glucose intolerance